{"id":"W2954619918","doi":"10.1158/1538-7445.am2019-ct200","title":"Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pemetrexed; Oncology; Population; Carboplatin; Progression-free survival; Docetaxel; Clinical endpoint; Paclitaxel; Bevacizumab; Randomized controlled trial; Chemotherapy; Cancer; Nivolumab; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003198593,0.001621442,0.002134866,0.0005365261,0.0005220628,0.001287764,0.00130076,0.001720089,0.01204464],"category_scores_gemma":[0.002668897,0.000739284,0.002633909,0.0006799891,0.001198334,0.0009579271,0.0007296416,0.004851041,0.001320275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001571482,"about_ca_system_score_gemma":0.002834846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001014,"about_ca_topic_score_gemma":0.003238062,"domain_scores_codex":[0.9986407,0.0008903273,0.00006251252,0.0001514672,0.0001315929,0.0001234976],"domain_scores_gemma":[0.9978799,0.0005304401,0.0005257431,0.0001759001,0.0001101451,0.0007779344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.961192,0.008727776,0.001963396,0.0004483048,0.001276081,0.00007259456,0.00005376567,0.0007431575,0.006305334,0.0001243237,0.003530986,0.01556225],"study_design_scores_gemma":[0.8560187,0.1296593,0.008609948,0.00004292095,0.001341951,0.0001349724,0.00001803869,0.0009022761,0.001353126,0.0002072536,0.001685503,0.00002596769],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764251,0.002349489,0.001047963,0.0009549589,0.0001439154,0.005745084,0.008778151,0.0002312674,0.004323933],"genre_scores_gemma":[0.9772565,0.001103341,0.001653675,0.001313347,0.000230611,0.004257713,0.01108887,0.00007200657,0.003023827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01204464,"threshold_uncertainty_score":0.04029334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0380049710616801,"score_gpt":0.4185161436121033,"score_spread":0.3805111725504232,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}